The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.

The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.

Paclitaxel plays a central role in chemotherapy for breast cancer. Peripheral neuropathy, a well-known toxicity with paclitaxel, may be of interest in predicting the efficacy of paclitaxel therapy for patients with metastatic breast cancer. We performed a retrospective analysis assessing whether the...

Full description

Bibliographic Details
Main Authors: Ippei Fukada, Yoshinori Ito, Kokoro Kobayashi, Tomoko Shibayama, Shunji Takahashi, Rie Horii, Futoshi Akiyama, Takuji Iwase, Shinji Ohno
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5595337?pdf=render

Internet

http://europepmc.org/articles/PMC5595337?pdf=render

Similar Items